🇺🇸 FDA
Pipeline program

NBI-5788

NBI-5788-0201

Phase 2 small_molecule completed

Quick answer

NBI-5788 for Multiple Sclerosis is a Phase 2 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
NEUROCRINE BIOSCIENCES INC
Indication
Multiple Sclerosis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials